Metabolic profiling of cell line collections have become an invaluable tool to study disease etiology, 13 drug modes of action and personalized medicine. However, large-scale in vitro dynamic metabolic 14 profiling is limited by time-consuming sampling and complex measurement procedures. By adapting 15 an MS-based metabolomics workflow for high-throughput profiling of diverse adherent mammalian 16 cells, we establish a technique for the rapid measurement and analysis of drug-induced dynamic 17 changes in intracellular metabolites. This methodology is scalable to large compound libraries and is 18 here applied to study the mechanism underlying the toxic effect of dichloroacetate in ovarian cancer 19 cell lines. System-level analysis of the metabolic responses revealed a key and unexpected role of CoA 20 imbalance in dichloroacetate toxicity. The herein proposed strategy for large-scale drug metabolic 21 profiling is complementary to other molecular profiling techniques, opening new scientific and drug-22 discovery opportunities. 23
Introduction 24
A major bottleneck in drug discovery pipelines is the lack of mechanistic information on the targets of 25 selected lead compounds. Large-scale approaches enabling the characterization of cell responses to 26 external perturbations have therefore turned into highly relevant technologies in drug discovery and 27 development [1] [2] [3] [4] . Among these approaches, the systemic profiling of drug-induced changes in model 28 organisms at the mRNA and protein level 5,6 has provided invaluable insights into drug modes of action 29 (MoA) 7-9 , drug-drug interaction mechanisms 10 and drug repurposing 2,11 . Conceptually similar to 30 transcriptomics and proteomics platforms, metabolomics provides an orthogonal multi-parametric 31 readout aiming at quantifying the full spectrum of small molecules in the cell, the so-called 32 metabolome. Applied to drug discovery research, metabolome profiling of drug-perturbed cell lines in 33 vitro was key in revealing drug MoA and in identifying potential weaknesses in cellular drug response 34 as well as genetic polymorphisms associated with drug susceptibility 12-21 . 35 Metabolomics-based approaches have a notable advantage over existing functional genomics 36 platforms in that they enable an unparalleled throughput 22,23 . However, despite significant 37 advancements in high-resolution mass-spectrometry profiling of cellular samples 23-26 , efficient 38 experimental and computational workflows for large-scale dynamic metabolome profiling in 39 mammalian cells in vitro are lagging behind. Metabolome screenings that adopt classical metabolomics 40 techniques 27,28 are often hampered by a limited throughput, laborious sample preparation and the lack 41 of rigorous, yet simple, data analysis pipelines to interpret dynamic metabolome profiles. To address 42 these limitations, our group developed a high-throughput and robust method to perform large-scale 43 static metabolic profiling in adherent mammalian cells 29 , using a 96-well plate cultivation format 44 combined with time-lapse microscopy and flow-injection time-of-flight mass spectrometry 25 (TOFMS) . 45
Here, we extend this methodology to allow rapid sample collection and the analysis of dynamic 46 changes in the intracellular metabolome of diverse mammalian cell lines upon external perturbations. 47
We applied this methodology to profile the diversity of metabolic adaptive responses in five ovarian 48 cancer cell lines to an activator of pyruvate dehydrogenase (i.e. dichloroacetate) and a lactate 49 dehydrogenase inhibitor (i.e. oxamate). 50
The presented framework for in vitro large-scale dynamic metabolomics of perturbed adherent 51 mammalian cell lines is complementary to and scales with high-throughput growth-based phenotypic 52 screens of large compound libraries. Moreover, we provide a proof of principle that our approach can 53 characterize compound MoAs, and can generate testable predictions to elucidate the origin of drug 54 response variability. Such a platform may complement and improve the translational value of classical 55 in vitro phenotype-based drug screenings 30 , and provide insights on the mechanisms of action of small 56 molecules facilitating early stages of drug discovery [31] [32] [33] . 57 58 Results 59
High-throughput dynamic metabolic profiling of drug action in mammalian cell lines 60
Large-scale metabolic profiling of transient drug responses among diverse cell types necessitates new 61 methodologies enabling parallelized and rapid sample collection, high-throughput metabolic profiling 62 and an effective normalization approach for metabolomics data. Here, we developed a combined 63 experimental-computational approach enabling the rapid profiling of dynamic changes in the baseline 64 metabolic profile of diverse cell lines in parallel. This approach was applied here to study the metabolic 65 responses of five ovarian cancer cell lines to two enzyme inhibitors: dichloroacetate and oxamate. 66
In brief, the five different cell lines IGROV1, OVCAR3, OVCAR4, OVCAR8 and SKOV3 were grown in 67 parallel in 96-well plates for four days. Cells were exposed to the corresponding drug dose yielding 68 50% growth inhibition (GI 50 ) ( Table 1 ) and metabolomics samples were collected every 24 hours, 69 following the extraction protocol described in 29 and summarized in Supplementary Figure S1 . In the 70 present study, nine replicate plates were prepared: one plate served to continuously monitor cell 71 growth via cell confluence by time-lapse microscopy using an automated multi-well plate reader 72 ( Figure 1 ), while the remaining plates are used for metabolome extraction immediately before, and at 73 24, 48, 72 and 96 hours after drug exposure (Supplementary Figure S1) . At each sampling time point, 74 one plate was used to generate cell extract samples, while the second plate served to determine 75 extracted cell numbers per well using bright-field microscopy 29 . Cell extract samples were profiled by 76 flow injection analysis and time-of-flight mass spectrometry (TOFMS) as described previously 25 , 77 enabling high-throughput analysis of large sample collections. The detected ions were annotated 78 based purely on the accurate mass, and by assuming that deprotonation is the most frequent and 79 reliable form of ionization in negative mode. By matching measured m/z against calculated 80 monoisotopic masses of metabolites listed in the Human Metabolome Database (HMDB 34 ) and in the 81 genome-scale reconstruction of human metabolism (Recon 2 35 ), we putatively annotated 2482 ions 82 (Supplementary Data Table S1 ). Importantly, in absence of prior chromatographic separation, FIA-83 TOFMS cannot distinguish isobaric metabolites as well as in-source fragments that are detected at the 84 identical exact mass. 85
To estimate time-dependent (e.g. drug-induced) changes of intracellular metabolites from non-86 targeted metabolomics data we employed a regression-based analysis strategy. This approach 87 compares transient changes in the metabolome of drug-treated cells against steady-state unperturbed 88 cell metabolic profiles (Supplementary Figure S2 ). Steady-state metabolic profiles of unperturbed cells 89 were determined following the approach described in 29 , which is here briefly summarized. By 90 definition, the intracellular concentrations of metabolites at steady state are constant in time. Hence, 91 in samples from unperturbed growing cells for each metabolite i in cell line j, measured intensities, I j,i , 92 scale proportionally with the metabolite abundance in the cell [m i ], times the extracted cell number 93 (N c , derived from bright-field microscopy 29 , see Supplementary Figure S3 ): 94
Hence, we can model the measured metabolite intensities in a given cell line as follows: 96
where β i is an offset value representing the experimental MS background signal, and α j,i represents the 98 abundance of metabolite i per cell. Notably, α j,i contains an unknown scaling factor that is reflective of 99 the fundamental proportionality between metabolite concentration and MS signal intensity. For each 100 metabolite, we use a multiple regression scheme to fit the linear model and regress the cell line-101 specific α values and the offset β across all cell lines at once (Supplementary Figure S4 ). To assess the 102 reliability of the parameter estimates, each fitted parameter is associated with a p-value (F statistic 103 with the hypothesis that the coefficient is equal to zero). It is worth noting that this procedure allows 104 systematically filtering out: (i) annotated ions which are unlikely to originate from extracted cells, 105 because the measured ion intensity does not exhibit any dependency with the cell number, and (ii) 106 ions for which the measured intensities are below the detection limit, and the estimated cell line- Figure S1 and S3). For each time point, the difference between measured and 122 expected metabolite intensities is expressed in log 2 fold-changes, and significance is quantified by 123 means of p-values from t-test analysis. In the following, our metabolome profiling pipeline was applied 124 to investigate the metabolic response to two small-molecule agents, dichloroacetate and oxamate 125 ( Oxamate is a competitive inhibitor of lactate dehydrogenase (LDHA) with respect to pyruvate 47 (Figure  204 2b). A growing body of evidence indicates that oxamate induces apoptosis exclusively in cancer 205 cells 47,48 . According to current theory, the inhibition of lactate production, together with typically high 206 glycolytic rates in cancer cells, causes an over-production of toxic superoxide by the mitochondrial 207 electron transport chain. Since both drugs decrease lactate secretion rates (Supplementary Figure S8) , 208 oxamate treatment could lead to similar metabolic adaptive mechanisms as dichloroacetate. 209
In our dynamic metabolome profiling data, we observed a significant accumulation of intermediates 210 in TCA cycle upon oxamate treatment, and a concomitant reduction of intracellular ATP levels, in 211 accordance with previous findings 49 . Overall, we found that the significant metabolic changes common 212 to all cell lines locate in central metabolic pathways like oxidative phosphorylation and nucleotide 213 metabolism (Figure 2c ). In particular, we observed a consistent and large accumulation of sorbitol and 214 sedoheptulose 7-phosphate ( Figure 2b) . Overall, changes induced by oxamate were largely different 215 from those induced by dichloroacetate (Figure 3a-c) , suggesting for radically different metabolic 216 adaptive strategies. Unlike PDH activation by dichloroacetate, inhibition of lactate dehydrogenase 217 seems to redirect intermediates in upper glycolysis to other pathways, such as NADPH-dependent 218 reduction of glucose to form sorbitol, or the pentose phosphate pathway (as indicated by accumulation 219 of sedoheptulose 7-phosphate, Figure 2b ). Both metabolic responses are known to counteract 220 oxidative stress 50,51 . Interestingly, we also observed a marked reduction in the level of N-Acetylaspartic 221 acid (Figure 2b) , a potent oxidative stress agent 52 associated with poor prognosis in ovarian cancer 53 . 222 The marked differences between metabolic adaptive responses to oxamate and to dichloroacetate 223 reinforce our previous observation of a selective functional link between CoA metabolism and the 224 mode of action of dichloroacetate. 225 226
Conclusions/Discussions 227
In this study, we present a novel experimental and computational workflow that enables a systematic 228 and high-throughput investigation of dynamic changes in the intracellular metabolism of adherent 229 mammalian cells upon environmental perturbation. Our methodology provides a novel way to perform 230 high-throughput dynamic metabolic screens in adherent cell lines, and addresses several challenges in 231 computational data normalization and interpretation. Limitations concern both the extraction of the 232 most informative features from non-targeted profiling data, and the general ability to systematically 233 infer testable molecular hypotheses from non-targeted metabolomics screens. Our approach offers a 234 higher throughput than previous state-of-the-art metabolomics methodologies for adherent 235 mammalian cells 27,28,54,55 by using a miniaturized parallel 96-well cultivation system, a simple 236 metabolite extraction procedure and automated time-lapse microscopy. We additionally exploit the 237 unique advantages of flow-injection high-resolution MS-based metabolomics that provides 238 exceptional throughput and repeatability, and has become an invaluable tool 56-59 for exploratory 239 studies and the profiling of large sample collections. Altogether, our methodology offers new scientific 240 and clinical opportunities for large-scale in vitro exploratory metabolome drug screenings and a 241 complementary tool to more targeted approaches 60 . 242
A major challenge common to many high-content screenings is the computational analysis of large 243 datasets for the generation of testable predictions. Here, we implemented a systematic data 244 processing and analysis pipeline that allows comprehensively interpreting dynamic metabolic profiles 245 (Supplementary Figure S2 ). While changes in metabolite abundance do not necessarily correspond to 246 changes in conversion rates (i.e. fluxes), altered metabolite pools can be reflective of functional 247 changes in the cell 61 . By investigating the dynamic responses to the perturbing agents dichloroacetate 248 and oxamate, we proposed a previously undescribed role of pantothenate and CoA in mediating the 249 toxicity of dichloroacetate. Therapeutically, high dosages of dichloroacetate are needed in order to 250 effectively suppress tumour growth 37 , limiting further development and usage of this compound in 251 clinics. Nevertheless, our results suggest that compounds affecting CoA production are likely to exhibit 252 strong epistatic interactions with dichloroacetate. Combining dichloroacetate with activators of PANK 253 enzymes 62 could hence potentially increase the therapeutic efficacy and allow reducing the 254 dichloroacetate dosage, offering an attractive approach to reduce dichloroacetate side effects. In light 255 of the promising initial evidence that we provided here, this possibility warrants more attention in 256 future studies. 257
We have shown here that our experimental and computational framework for high-throughput drug 258 metabolome profiling can provide key insights into the cellular response to bioactive compounds. As 259 such, this technique can become a powerful complementary tool to aid lead selection at early stages 260 of drug discovery, and to predict compound modes of action, similar to approaches exploiting large 261 compendia of cellular gene expression profiles 21 . For instance, comparative analysis can reveal 262 uncharacterized compounds featuring metabolic responses similar to drugs with known molecular 263 targets 2 . Our proof-of-principle example illustrates how in vitro high-content metabolic drug profiling 264 can provide a first coarse-grained characterization of a compound mode of action. It is worth noting 265 that the here presented methodology is widely applicable to more clinically relevant models, like 266 primary cells, and can be a powerful tool in guiding the rational design of in vivo low-throughput follow-267 up studies. Despite the difficulty in translating the relevance of in vitro phenotypes into in vivo 268 outcomes 63 , we envisage that this approach can be applied to the profiling of large sets of bioactive 269 compounds 31 in a large cohort of cell lines 64, 65 Figure S10 ). For each cell line, 466 cells were seeded in 135 µL of fresh medium in 96-well plates according to the previously calculated optimal 467 density. After 24 h, oxamate and dichloroacetate, dissolved at different concentrations in 15 µL of medium, 468
were added to the cells in triplicates. Immediately upon drug addition, 24 h, 48 h and 72h after drug 469 exposure, all wells were imaged using a Spark™ 10M (TECAN) plate reader, and the cell confluence was 470 determined. For each condition and cell line, the growth rate was obtained by fitting an exponential curve 471 to the cell confluence measurements. The relative growth rate inhibition upon different drug 472 concentrations was then fitted by a sigmoidal curve (Supplementary Figure S10 ) and the drug concentration 473 causing a 50% reduction in growth rate (GI 50 ) was estimated from the fitted curve (Figure 3b ). 474
Metabolomics experiments. Cell lines were plated in nine 96-well plates according to the optimal density 475 previously calculated, using 135 µL of medium. To minimize the effect of evaporation, the outmost rows 476 and columns of the plate were omitted, and filled with PBS instead. After 24 h, cells were perturbed with 477 15 µL of medium containing drug concentrations close to the respective GI 50 for each cell line. When the 478 calculated GI 50 dose could not be reached due to limited solubility, the highest concentration possible was 479 of a total of 30 α-keto acid compounds (selected via KEGG SimComp search 521 http://www.genome.jp/tools/simcomp/) to the metabolite list for annotation. The monoisotopic mass is 522 calculated for each of the listed metabolites based on its sum formula. A list of expected ion masses 523 corresponding to the listed metabolites is subsequently generated, considering only ionization by 524 deprotonation (-H+) in negative mode electrospray ionization. Subsequently, these theoretical ion masses 525 are searched against the detected ion mass-to-charge ratios (m/z) within a tolerance of 0.003 amu. The 526
final list of annotated ions is compiled considering the best metabolite match (i.e. smallest difference to 527 the expected mass) for each ion. 528
Data processing and computational analysis for steady state metabolome data. All steps of data 529 processing and further analysis were performed in Matlab 2015b (The Mathworks, Natick). For steady-state 530 metabolome profiles, the bioinformatics pipeline is described in 29 and is here summarized. Multiple 531 regression analysis to estimate the relative metabolite concentrations at steady state was performed using 532
the Matlab fitlm function. This function infers model parameters α (cell line-specific) and β by minimizing 533
the Euclidian distance between measured metabolite intensities and model predicted ones. It is worth 534 noting that the β represents the MS background signal, or in other words the ion intensity when no cells 535 are extracted. Hence, this particular parameter is independent from cell types. Because of the difficulties 536 in reliably estimating the extracted cell number from bright-field microscopy images above a confluence of 537 80% (Supplementary Figure S3 ), and the observed deviation from metabolic steady-state (Supplementary 538 Figure S4 ), we excluded all metabolome measurements taken above this cell density threshold. For each 539 metabolite, we solve the following linear model: 540 
Where I cell1,1 is the measured metabolite intensity in cell-line 1 /sample 1 , N cell1,1 is the corresponding number 542 of cells extracted in cell-line 1 /sample 1 . Cell line specific αs and β are the unknown parameters to be fitted. 543 We selected the metabolites exhibiting a significant alteration in at least one cell line using a one-way 544 ANOVA test, including a step correcting for multiple hypothesis testing 67-69 (Supplementary Figure S12) . 545
Data processing and computational analysis for dynamic drug-induced metabolome changes. The full 546 matrix of dynamic metabolic profiles after dichloroacetate and oxamate treatments is provided in 547
Supplementary Data Table S2 . In order to deduce a specific metabolic fingerprint induced by an external 548 perturbing agent, we (i) selected the most significant metabolic changes conserved across the cell lines, (ii) 549
performed pathway enrichment analysis on the resulting list of metabolites, and (iii) analyzed response 550 variability across all cell lines. 551 (i) Separately for each perturbation (i.e. oxamate and dichloroacetate), we extracted the most 552 significant and prominent metabolic changes that are conserved across the different cell lines. 553
To this end, for each individual metabolite time course we calculated the median of maximum 554 absolute fold changes and the product of lowest p-values across cell lines. As a result, each 555 metabolite is associated with a unique median fold-change and p-value, summarizing the 556 effect of the perturbation on all cell lines. 557
(ii) Metabolites with an absolute log 2 fold-change ≥ 1 and a combined p-value ≤ 1e-10 are tested 558 against KEGG metabolic pathways. Pathways with an overrepresented number of altered 559 metabolites are selected based on a hypergeometric statistical test and p-value correction for 560 multiple tests 67,68 . 561
(iii) Metabolites that exhibit cell line-specific responses to a given perturbation are selected on the 562 basis of the response variability exhibited across the different cell lines. The standard deviation 563 for each metabolite was calculated from the aforementioned maximum fold changes in each 564 cell-line time course, and metabolites with a standard deviation ≥ 1.5 are retained and 565 subjected to pathway enrichment analysis (Supplementary Figure S12) . 566
Cell growth and segmentation. All procedures for cell growth monitoring and image analysis were adopted 567 from 29 , and are here briefly summarized. The monitoring of cell growth during the entire course of the 568 experiment was performed using A TECAN Spark 10M plate reader was used to monitor live adherent cell 569 cultures directly in the 96-well culture plate. The choice of image acquisition frequency depends on how 570
fast are the expected growth dynamic changes. Here, we selected a time frequency of 1.5 hours as a 571 reasonable tradeoff between the fastest doubling time among our cell lines (approx. 20 hours) and the time 572 it takes to acquire the images for a full plate on the TECAN plate reader (approx. 30 min). It is worth noting 573 that our procedure can be adapted to other commercially available plate readers. Full detail on bright-field 574 image processing and the extraction of cell confluence and average adherent cell size is described in 29 575
(MATLAB code available for download). 
